Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)

 Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)

Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)

Shots:

  • The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD
  • The two P-III study resulted in meeting 1EPs @16 wks. with no venous thromboembolic events (VTEs), major adverse cardiovascular events (MACE) & deaths rates
  • Olumiant (baricitinib, 2mg) indicated for moderate-to-severe RA who have had an inadequate response to TNF antagonist therapies and is approved in 50 countries including the US, EU, and Japan. In Dec,2009 Lilly and Incyte collaborated to develop and commercialize baricitinib for inflammatory and autoimmune diseases

Click here  to read full press release/ article | Ref: PRNewswire | Image:Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post